Tyrosinase (Canine) (TYR)

Canine tyrosinase is a membrane-bound, copper-containing enzyme primarily localized in the melanosomes of melanocytes, where it serves as the rate-limiting catalyst for melanin production [1, 14]. It facilitates the hydroxylation of L-tyrosine to L-DOPA and the subsequent oxidation of L-DOPA to dopaquinone, essential steps in the synthesis of both eumelanin and pheomelanin [1, 12, 17]. In veterinary medicine, canine tyrosinase is a highly significant therapeutic target due to its overexpression in malignant melanomas, particularly the aggressive oral form common in dogs [6, 14]. The primary therapeutic approach involves the use of the Oncept vaccine, a xenogeneic DNA vaccine encoding human tyrosinase [2, 3]. Because the human protein is roughly 85% to 92% homologous to the canine version, it is sufficiently foreign to break immune tolerance while remaining similar enough to generate cross-reactive antibodies and cytotoxic T-cell responses against the dog's tumor cells [4, 6, 7]. Beyond immunotherapy, the expression of tyrosinase is used as a diagnostic biomarker for identifying amelanotic melanomas and monitoring tumor differentiation [14, 15]. Therapeutic challenges include variable clinical efficacy and the potential for autoimmune-mediated destruction of normal melanocytes, which can lead to localized or systemic vitiligo [4, 8].

Other names

Monophenol monooxygenaseL-DOPAquinone:oxygen oxidoreductaseTyrosinaseEC 1.14.18.1SK29-AB

Induction of a cross-reactive immune response (both humoral and cellular) against endogenous canine tyrosinase through xenogeneic DNA vaccination using human tyrosinase sequences.